Navigation Links
Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries

BANNOCKBURN, Ill., April 18, 2012 /PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries.  

Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer.  Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities.

Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer.  Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.

About Pinnacle Biologics

Pinnacle Biologics Inc., a privately held bio-pharmaceutical company, specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. The company is based in the U.S.A with its headquarters in Bannockburn, Illinois; and its European subsidiary, Pinnacle Biologics BV,is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About Bioprojet Pharma

Bioprojet Pharma is a privately held European pharmaceutical company with is headquarters in Paris, France.  Bioprojet is a leading European research based specialty pharmaceutical company involved in the design and development of compounds from pre-clinical to Phase III.  The company markets pharmaceutical products across Europe.

Contact Information:
Pinnacle Biologics Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

SOURCE Pinnacle Biologics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago
2. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
3. Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
4. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
5. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
8. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
9. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):